433939-83-4

Basic information

• Product Name: Benzonitrile, 4-ethenyl-2-fluoro- (9CI)
• Synonyms: Benzonitrile, 4-ethenyl-2-fluoro- (9CI);2-fluoro-4-vinylbenzonitrile
• CAS NO: 433939-83-4
• Molecular Formula: C₉H₆FN
• Molecular Weight: 147.1490432
• Product Categories: HALIDE
• Mol File: 433939-83-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzonitrile, 4-ethenyl-2-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-ethenyl-2-fluoro- (9CI)(433939-83-4)
• EPA Substance Registry System: Benzonitrile, 4-ethenyl-2-fluoro- (9CI)(433939-83-4)

Safety Data

• Hazardous Substances Data: 433939-83-4(Hazardous Substances Data)

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 942282-42-0 2-fluoro-4-(2-hydroxyethyl)benzonitrile 
• 85070-67-3 2-fluoro-4-methylbenzonitrile 
• 1097871-99-2 (4-cyano-3-fluorophenyl)acetic acid 
• 1255207-56-7 2-(4-cyano-3-fluorophenyl)ethyl methanesulfonate 
• 7486-35-3 tri-n-butyl(vinyl)tin 

Downstream Products

• 1255207-55-6 2-fluoro-4-oxiran-2-ylbenzonitrile 
• 222978-02-1 2-fluoro-4-(hydroxymethyl)benzonitrile 

Relevant articles and documents

CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS

The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.